Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.61 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095386 | 0.87 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL3867030 | 0.87 | TLR7 (0.79) | TLR7TLR8 | |
| SCHEMBL3869663 | 0.86 | TLR7 (0.81) | TLR7TLR8 | |
| SCHEMBL6093743 | 0.85 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL6773544 | 0.84 | TLR7 (0.51) | TLR7TLR8 | |
| SCHEMBL3864075 | 0.84 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL3355132 | 0.84 | TLR7 (0.64) | TLR7TLR8TP53MAPT | |
| SCHEMBL6674213 | 0.83 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL4078594 | 0.83 | TLR7 (0.43) | TLR7TLR8TP53MAPTSMN1; SMN2 | |
| SCHEMBL1490788 | 0.83 | TLR7 (0.43) | TLR7TLR8TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1249062-C | Substituted imidazopyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2006-04-05 | — | — | CN | claimed |
| CN-1599740-A | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2005-03-23 | — | — | CN | claimed |
| US-20040186128-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-23 | — | — | US | claimed |
| EP-1451187-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | claimed |
| CN-1478090-A | Substituted imidazopyridines | 3M | 2004-02-25 | — | — | CN | claimed |
| US-20030186949-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | claimed |
| US-20030162806-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-28 | — | — | US | claimed |
| WO-2003050118-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | claimed |
| US-6545016-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | claimed |
| US-20020107262-A1 | SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-08 | — | — | US | claimed |
| CN-100402528-C | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2008-07-16 | — | — | CN | disclosed |
| CN-101220028-A | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2008-07-16 | — | — | CN | disclosed |
| CN-100387597-C | Amido-substituted imidazopyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2008-05-14 | — | — | CN | disclosed |
| CN-100372846-C | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2008-03-05 | — | — | CN | disclosed |
| US-7098221-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-29 | — | — | US | disclosed |
| WO-2003050117-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6545016-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6545017-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6525064-B1 | Immune response modifiers; can induce the biosynthesis of various cytokines; | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-20020107262-A1 | SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186128-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | TLR7 75/4885TLR8 55/4885TP53 169/4885 |
| US-20020107262-A1 | SUBSTITUTED IMIDAZOPYRIDINES | IRF3, IFNG, EIF2AK2 | TLR7 61/4885TLR8 70/4885TP53 117/4885 |
| US-20030162806-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | TLR7 75/4885TLR8 55/4885TP53 169/4885 |
| US-20030186949-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | TLR7 75/4885TLR8 55/4885TP53 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.